8,668 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Unigestion Holding SA

Unigestion Holding SA bought a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 8,668 shares of the biotechnology company's stock, valued at approximately $2,672,000.

A number of other institutional investors have also recently bought and sold shares of UTHR. Newbridge Financial Services Group Inc. purchased a new stake in shares of United Therapeutics during the 4th quarter valued at $25,000. Dunhill Financial LLC grew its position in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares during the period. State of Wyoming acquired a new stake in United Therapeutics during the fourth quarter worth about $62,000. Millstone Evans Group LLC purchased a new position in shares of United Therapeutics in the 4th quarter worth about $67,000. Finally, Natixis acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $85,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

Shares of UTHR stock traded down $0.23 during mid-day trading on Wednesday, reaching $323.97. 390,841 shares of the company were exchanged, compared to its average volume of 440,270. The business's 50 day simple moving average is $300.11 and its 200 day simple moving average is $334.17. The company has a market capitalization of $14.61 billion, a P/E ratio of 14.23, a P/E/G ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a fifty-two week low of $266.98 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the previous year, the firm earned $6.17 EPS. The company's revenue was up 17.2% on a year-over-year basis. On average, analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research reports. Morgan Stanley raised their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a report on Thursday, May 1st. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. HC Wainwright reiterated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a research report on Monday, April 21st. Finally, JPMorgan Chase & Co. decreased their target price on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $393.00.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares of the company's stock, valued at $2,703,424. The trade was a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the sale, the executive vice president now directly owns 36,781 shares in the company, valued at $11,261,606.58. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,500 shares of company stock worth $16,923,950 over the last quarter. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.